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Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the coronavirus 2 that causes 
severe acute respiratory syndrome (SARS-CoV-2). More discussion is required to achieve the balance between 
clinical benefit and risk in the treatment of acute coronary syndrome (ACS) patients with COVID-19. The current 
COVID-19 pandemic prompts the need to evaluate criteria for indication and efficacy of the general safety 






 The coronavirus disease 2019 (COVID-19) caused by the 
severe acute respiratory syndrome (SARS-CoV-2) virus has been at 
pandemic levels since March 2020. The Covid-19 pandemic had a 
significant impact on healthcare, involving the management of acute 
coronary syndrome (ACS). ACS encompasses a wide range of clinical 
manifestations, from ST-segment elevation myocardial infarction 
(STEMI) to Non-ST-segment elevation Acute Coronary Syndrome 
(NSTE-ACS), which includes NSTEMI and unstable angina pectoris 
(UAP). Regarding the COVID-19 era, resources from regular hospital 
services, such as Cardiac Catheterization Laboratory (CCL) facilities, 
have been redirected to focus on the care of COVID-19-infected 
patients. There is still a concern that the public would delay seeking 
emergency help due to the worry of contracting COVID-19 in health 
facilities.1,2 It might cause serious consequences, particularly in 
conditions including acute coronary syndrome (ACS), where prompt 
treatment and coronary revascularization have been shown to reduce 
mortality and morbidity. Isolated reports were disclosed by local and 
regional authorities that the current pandemic is linked to a reduction 
in both presentations with acute myocardial infarction and revascular-
ization procedures during the pandemic. 
 The risk of nosocomial viral transmission must be weighed 
against the benefits of revascularization in managing ACS in patients 
with confirmed or suspected COVID-19. In the event of a highly 
contagious pandemic, healthcare workers must remain vigilant and 
adhere to all safety precautions when within CCL.3,4
2. Revascularization 
 The necessary reorganization of healthcare facilities to 
combat the COVID-19 pandemic has highlighted numerous major 
challenges regarding the prioritization of invasive cardiac procedures. 
A systematic approach was needed to distinguish between people in a 
condition that allows invasive cardiac procedures to be postponed and 
those who need to be treated immediately. Maintaining the current 
level of care and providing timely revascularization to patients with 
ACS remain a challenge. All patients should be screened for 
SARS-CoV-2 as soon as possible after initial medical contact, regardless 
of the revascularization method used. Both coronary artery bypass graft 
(CABG) and percutaneous coronary intervention (PCI) procedures may 
be postponed in the majority of chronic coronary syndrome (CCS) 
cases.4,5
 The timely reperfusion of STEMI patients should not be 
compromised even during the current pandemic. STEMI patients with a 
negative result in the rapid screening test for COVID-19 underwent 
standard STEMI management according to the 2017 ESC guideline for 
STEMI (Figure.1). Primary PCI is still the treatment of choice for 
reperfusion. Primary PCI routes may be postponed during the pandem-
ic (according to various experiences - up to 60 minutes) due to the 
delay in administering therapy and the deployment of protective 
measures. If the target revascularization time was not able to be 
achieved and fibrinolysis was not a contraindication, fibrinolysis should 
be used as the first line of treatment. Furthermore, if severe pneumonia 
symptoms develop, the patient should receive conservative treatment 
https://doi.org/10.21776/ub.hsj.2021.002.03.1
Received 12 May 2021; Received in revised form 12 June 2021; Accepted 28 March 2021
*Corresponding author at: Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya 
dr. Saiful Anwar General Hospital, Malang, Indonesia
E-mail address: sasmojowidito@yahoo.com (S. Widito).
Available online 1 July 2021





Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya – dr. Saiful Anwar General Hospital, Malang, Indonesia.
1*
Editorial Heart Sci J 2021; 2(3): 1-4
in an isolation inpatient facility. However, in case an unstable hemody-
namic sign evolves without the signs and symptoms of severe pneumo-




 On the other hand, revascularization strategy for NSTE-ACS 
should be directed by risk stratification. Patients have to be classified 
into four risk groups (low risk, intermediate-risk, high risk, and very 
high risk) and treated appropriately. NSTE-ACS patient with a negative 
result in the rapid screening test for COVID-19 undergoes NSTE-ACS 
standard treatment according to the 2020 ESC guideline for NSTE-ACS. 
After initial medicinal therapy, revascularization of NSTE-ACS patients 
with confirmed or suspected COVID-19 but no symptoms may be 
delayed until negative SARS-CoV-2 test results are verified. Non-inva-
sive testing could accelerate risk assessment, prevent unnecessary 
invasive procedures, and allow for early patient discharge. Patients 
with a positive SARS CoV-2 test result should be transported to a 
facility that is prepared to treat COVID-19-positive patients for revascu-
larization treatment. Similar to STEMI patients with a confirmed or 
suspected case of COVID-19, NSTE-ACS patients presenting with 
unstable hemodynamic signs without the signs and symptoms of severe 
pneumonia, invasive strategy is recommended in isolated CCL if the 
benefits of revascularization outweigh the risks. Nonetheless, in the 
COVID-19 age, when the health system is overburdened and CCL or 
operators are not readily available, non-invasive conservative 
treatment with early hospital discharge and scheduled clinical 
follow-up may be recommended.5,7
Figure 1. Management of STEMI during COVID-19 Pandemic
Figure 2. Recommendation of Management of NSTE-ACS during COVID-19 Pandemic
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3. Cath Lab Operation  
 During the COVID-19 era, case decisions in the CCL should 
be individualized, taking into account carefully weighting the balance 
of staff exposure and patient benefit. Thorough infection management 
with adequate personal protective equipment (PPE) should be a 
priority. Additionally, repeated wipe downs of frequently handled 
objects in control rooms (e.g., keyboards, doorknobs, etc) should be 
done regularly. Furthermore, when it’s feasible, all items that cannot be 
adequately sanitized after each case should be discarded to prevent the 
risk of cross-contamination. Regular meetings and conferences should 
be conducted through the internet or over-the-phone connections.9,10
 During the procedure, all CCL employees should wear N95 
masks, protective glasses, disposable hats, full face shields, surgical 
gloves, disposable gowns, and shoe coverings. Full-face masks are 
recommended since they offer additional facial protection. Lead aprons 
should be worn beneath the PPE to avoid contamination. The lead coats 
and the room should be sanitized according to the recommendation 
from the infection control team after the procedure. UV light and 500 
ppm diluted bleach, or other disinfectants, can be used to disinfect the 
area. Hand hygiene is particularly important before and after PCI to 
keep medical professionals and patients safe. It is not recommended to 
use non-invasive ventilation or a high-flow nasal cannula during PCI to 
prevent aerosol dissemination. While performing PCI, these protective 
measures aim to protect clinicians from infectious sources such as 
airborne, droplet, and direct contact.3,4,9,10
4. Conclusion
The COVID-19 pandemic has made a substantial impact on the health-
care system and medical personnel's clinical behavior. Fibrinolysis may 
be used first for STEMI patients with confirmed or suspected COVID-19. 
PCI could be reserved for people who have failed fibrinolysis in STEMI 
if CCL for COVID-19 patients is available. Revascularization of 
NSTE-ACS patients with confirmed or suspected COVID-19 but free 
form symptoms following medical treatment may be postponed until 
negative SARS-CoV-2 test results are validated. The data on safeguard-
ing measures regarding the current pandemic in the catheterization 
Figure 3. Guidance for (A) Donning and (B) Removing Personal Protective Equipment (PPE) in COVID-19 Era
laboratory is limited. Personnel safety plays an essential role in prevent-
ing in-hospital virus transmission and contamination.
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